Donislecel (Lantidra)

概览

Donislecel is an allogeneic pancreatic islets cellular therapy indicated for the treatment of type 1 diabetes

作用机制

As donislecel-jujn is a pancreatic islet cellular therapy, its mechanism of action stems from the secretion of insulin by the β- cells in the transplanted islet cells. Pancreatic islets regulate blood glucose levels through the secretion of multiple hormones in response to increases or decreases in blood glucose. Endocrine cells within pancreatic islets release insulin, glucagon, somatostatin, pancreatic peptide, and ghrelin. Insulin stimulates glucose uptake by peripheral tissues; glucagon mobilizes glucose from the liver into circulation; somatostatin inhibits both α- and β-cell secretions; pancreatic peptide inhibits pancreatic exocrine secretion, and ghrelin inhibits insulin secretion.

适应症

Donislecel-jujn is an allogeneic pancreatic islet cellular therapy indicated for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education. Use donislecel-jujn in conjunction with concomitant immunosuppression.

• Type 1 Diabetes Mellitus